AEVEX Corp.
AVEX
$10.20
+10.15%
AEVEX Corp. is a defense technology company that designs and delivers next-generation navigation and autonomy systems, uncrewed aerial and surface systems, precision strike solutions, and full-spectrum airborne ISR capabilities, sold primarily to agencies within the U.S. Department of War, Special Operations Forces, the Intelligence Community, and allied international partners. The company positions itself as a pure-play defense-tech platform built for the modern battlespace, differentiating itself through speed of delivery and adaptable mission solutions rather than the large-scale program-of-record model of legacy primes like Lockheed Martin or Northrop Grumman. The investor narrative is dominated by its April 2026 NYSE debut, which was framed by media coverage as an explosive IPO that signaled intense institutional demand for pure-play defense-tech names aligned with drone warfare and ISR trends amid heightened geopolitical tension, including a US-Iran conflict backdrop. Since then, the debate has shifted sharply from IPO euphoria to questions about post-listing execution, insider selling dynamics, and whether the company's roughly doubling of year-over-year revenue can be sustained against a stock that has lost more than half its value from its post-IPO peak.…
AVEX
AEVEX Corp.
$10.20
Related headlines
Investment Opinion: Should I buy AVEX Today?
Rating: Hold (speculative, catalyst-dependent). The core thesis is that AVEX pairs genuinely exceptional top-line momentum — 99.53% YoY revenue growth to $201.79 million in Q2 2026 — with a valuation that has already de-rated hard (PS compressed from 5.85x at Q2 2026 to 3.99x now, EV/EBITDA 54.09x, price $10.20 versus a $40.48 peak), but the absence of published analyst price targets and the stock's -77.12% max drawdown mean the risk/reward is unresolved until a clean earnings print or contract award confirms the growth is durable. Analyst consensus is constructive but static — two Buy/Outperform-equivalent ratings plus one Overweight against a single Neutral and zero Sells across six covering analysts, with RBC reiterating Outperform on October 22, one day after the 32% single-session gap — which anchors the view that the selloff is valuation- and supply-driven rather than fundamental, but also that no one is stepping up to re-rate the name yet.
Supporting evidence: (1) valuation — at $10.20 against consensus EPS of $1.335 (tight band of $1.1337 to $1.43149), the implied forward multiple is roughly 7.6x, a dramatic discount to the 54.09x EV/EBITDA and 3.99x PS trailing figures; (2) growth — revenue nearly doubled YoY and rose sequentially from $121.24M (Q3 2025) to $157.31M (Q4 2025) to $216.69M (Q1 2026) to $201.79M (Q2 2026), with consensus revenue of $1.35 billion implying roughly 60%+ growth over the trailing annualized run-rate; (3) profitability trend — gross margin improved from 14.09% in Q2 2025 to 23.61% in Q2 2026 and operating margin from -2.30% to 7.62%, with net income swinging from -$11.84 million to +$2.33 million; (4) balance sheet — current ratio of 5.47 and debt-to-equity of 0.43 mean the drawdown is a pricing event, not a solvency event, though free cash flow is negative (PCF -17.68) and the 0.29% dividend yield with a -5.90 payout ratio offers no income support.
Risks and conditions: the three biggest threats are (a) growth deceleration toward the low end of the $1.19 billion revenue estimate, which would leave the 21.78% gross margin and 1.00% operating margin unable to support even the current multiple; (b) continued post-lockup insider supply, given the October 21 gap from $14.34 to $9.68 and the fresh $9.26 low on November 5; and (c) the thin profit layer — Q2 net income of $2.33 million on $201.79 million of revenue, with $3.98 million of quarterly interest expense consuming a meaningful share of $15.37 million of operating income. This Hold would upgrade to Buy if Q3 revenue annualizes near the $1.35 billion consensus and the stock reclaims $14.34 (the pre-breakdown level), or downgrade to Sell on a break below $9.26 that confirms deceleration. Verdict: fairly valued to modestly undervalued relative to its own short valuation history (PS 3.99x versus 5.85x at Q2) but at a premium to legacy Aerospace & Defense peers on sales and EBITDA — the discount only becomes real if the ~100% growth rate holds.
Sign up to view all
AVEX 12-Month Price Forecast
AVEX presents a genuine tension between exceptional fundamentals and a broken technical and sentiment profile: revenue nearly doubled YoY with margins expanding sharply, the balance sheet is liquid (current ratio 5.47, debt-to-equity 0.43), and the implied forward multiple of roughly 7.6x on $1.335 consensus EPS looks cheap against 54.09x EV/EBITDA trailing. Against that, the stock has lost 77.12% from peak, the October 21 gap from $14.34 to $9.68 is consistent with a lockup or block-sale event, and the absence of published price targets means the market has no anchor for fair value. The neutral stance reflects that the bear evidence (accelerating declines, fresh lows, thin 21.78% gross margin versus a premium multiple) currently outweighs the bull case, but the analyst refusal to downgrade and the tight $1.1337-$1.43149 EPS estimate band argue against a Sell. I would upgrade to bullish on a Q3 print annualizing revenue near the $1.35 billion consensus plus a reclaim of $14.34, and downgrade to bearish on a decisive break below $9.26 or evidence of renewed insider supply.
Wall Street consensus
Six analysts cover AVEX, and the institutional ratings history shows a firmly constructive but static stance: RBC Capital reiterated Outperform on October 22 and October 12, Piper Sandler maintained Neutral on October 22, Needham reiterated Buy on August 13 and May 21, and JP Morgan held Overweight on May 26. The distribution skews bullish with two Buy/Outperform-equivalent ratings plus one Overweight against a single Neutral and no Sell ratings, and notably no downgrades appear even after the October price collapse — suggesting analysts view the selloff as valuation-driven rather than fundamental. However, the dataset does not include explicit price targets, so the consensus target price and implied upside cannot be calculated; based on the $10.20 current price and consensus estimated EPS of $1.335, the forward earnings power implied by analyst estimates is substantial relative to the current quote.\n\nThe estimate range is relatively tight on EPS — $1.1337 low to $1.43149 high around a $1.335 average — signaling reasonable conviction in the earnings outlook, while revenue estimates span $1.19 billion to $1.42 billion around a $1.35 billion average, a wider band that reflects contract-timing uncertainty. The high end of the revenue range would imply roughly 60%+ growth over the trailing annualized run-rate, assuming multiple expansion and new program awards, while the low end would imply a meaningful deceleration and possible margin compression as fixed costs absorb slower volume. The absence of published price targets in this dataset limits signal strength, but the pattern of reiterated (not upgraded) ratings alongside a 77% drawdown suggests analysts are waiting for a catalyst — likely a lockup resolution, a clean Q3 print, or a large contract award — before resetting their models.
Drowning in data?
Find the real signal!
Bulls vs Bears: AVEX Investment Factors
The bear case currently has stronger evidence: a -77.12% max drawdown, accelerating declines (-28.32% in one month, -53.99% in three), a 32% single-day gap on October 21, and a fresh low of $9.26 on November 5 all describe a broken momentum name with no confirmed base. The bull case rests on genuinely exceptional fundamentals — 99.53% revenue growth, positive Q2 net income of $2.33 million, a 5.47 current ratio, and a forward multiple near 7.6x on consensus EPS of $1.335 — plus the notable fact that no analyst has downgraded despite the collapse. The single most important tension is whether the ~100% growth is durable and contract-backed or a one-time surge: if Q3 revenue lands near the $1.35 billion annualized consensus, the 3.99x PS looks cheap and the stock re-rates; if growth decelerates toward the low end of the $1.19 billion range, the 21.78% gross margin cannot support even the current multiple. Until a clean earnings print or a large contract award resolves that question, the technical and sentiment evidence outweighs the fundamental case.
Bullish
- Revenue nearly doubled year-over-year: Q2 2026 revenue of $201.79 million grew 99.53% versus Q2 2025's $101.13 million, and the sequential trajectory ($121.24M in Q3 2025 to $216.69M in Q1 2026) shows a business scaling at a pace legacy primes cannot match. Even the Q1-to-Q2 dip of roughly 6.9% looks like contract timing rather than demand erosion given the near-doubling YoY.
- Forward EPS implies ~7.6x multiple: Consensus estimated EPS of $1.335 against the $10.20 price implies a forward multiple of roughly 7.6x, a dramatic discount to the 54.09x EV/EBITDA and 3.99x PS trailing figures. The estimate band is tight ($1.1337 to $1.43149), signaling reasonable analyst conviction in the earnings outlook.
- Analysts hold ratings through the collapse: Six analysts cover AVEX with two Buy/Outperform-equivalent ratings plus one Overweight against a single Neutral and zero Sells, and RBC reiterated Outperform as recently as October 22 — one day after the 32% single-session gap down. The absence of any downgrade suggests the selloff is viewed as valuation-driven rather than fundamental.
- Balance sheet can absorb the drawdown: A current ratio of 5.47 and debt-to-equity of just 0.43 mean the company has ample liquidity and modest leverage, so the 77.12% max drawdown is a market-pricing event rather than a solvency event. Q2 2026 net income of $2.33 million was positive, and Q1 2026 delivered $20.93 million of net income.
Bearish
- Falling knife with no base: The stock is at $10.20 versus a 52-week high of $40.48, down 74.8% from peak and 59.31% over six months, with a max drawdown of -77.12%. The 1-month change of -28.32% and 3-month change of -53.99% show the decline is accelerating rather than stabilizing, and the latest session's +10.15% bounce is trivial against a -23.33 point one-month relative underperformance versus SPY.
- Margins are thin versus the multiple: Gross margin of 21.78% and operating margin of 1.00% are far below legacy defense contractors that post mid-teens operating margins, yet the stock trades at 3.99x sales and 54.09x EV/EBITDA versus typical prime multiples of 1.5x-2.5x sales and 12x-16x EBITDA. The premium is only defensible if ~100% growth persists indefinitely.
- Profitability is barely breakeven: Trailing EPS of -$0.00049, ROE of -0.34%, and a net margin of -0.20% mean there is essentially no earnings cushion under the valuation. The trailing PE of -97.5 and negative PCF of -17.68 confirm the company is not yet generating meaningful cash returns, and the 0.29% dividend yield with a -5.90 payout ratio offers no income support.
- October gap signals a distribution event: The single-session collapse from $14.34 on October 20 to $9.68 on October 21 — roughly a 32% gap — is consistent with a lockup expiry, guidance reset, or large-block insider sale rather than ordinary selling. The stock has since failed to reclaim even $14, and the November 5 close of $9.26 established a fresh low beneath the panic print.
AVEX Technical Analysis
AVEX is in a pronounced downtrend following a violent post-IPO spike-and-fade, with the stock at $10.20 versus a 52-week high of $40.48 set on May 28, 2026 — meaning it trades at just 25.2% of its 52-week range and roughly 74.8% below its peak. The 6-month change of -59.31% and a max drawdown of -77.12% confirm this is a broken momentum name rather than a consolidation, and the price is now pressing against the lower boundary of its entire trading history. For investors, this positioning is a classic falling-knife profile: statistically cheap relative to its own range, but with no evidence yet of a durable base.\n\nShort-term momentum remains decisively negative and is diverging from an already weak longer-term trend. The 1-month change of -28.32% and 3-month change of -53.99% show acceleration in the pace of decline, with the most recent leg driven by a single-session collapse from $14.34 on October 20 to $9.68 on October 21 — a roughly 32% one-day gap that likely reflects a negative catalyst such as a lockup expiry, guidance reset, or large-block selling. The stock has since bounced to $10.20 (+10.15% on the latest session from a $9.26 close), but that rebound is small against the -23.33 percentage-point relative underperformance versus SPY over the past month, and the -49.08 point 3-month relative strength gap underscores how severely the shares are lagging the market.\n\nKey technical levels are now well defined: support sits at the $9.26 recent closing low (with the October 21 intraday panic low near $9.68 as the prior floor), while resistance is layered at $14.34 (the pre-breakdown level), then $20.89 (the June 30 rebound high), and ultimately the $40.48 all-time high. A decisive break below $9.26 would signal capitulation and open a vacuum with no historical support, while reclaiming $14.34 would be the first evidence of a tradeable bottom. Beta is not available in the provided data, but the realized volatility is extreme — a 77% peak-to-trough drawdown and multiple 20%+ single-day moves — implying position sizing should be a fraction of a typical Industrials allocation.
Beta
—
—
Max Drawdown
-77.1%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
—
Cumulative gain past year
| Period | AVEX Return | S&P 500 |
|---|---|---|
| 1m | -28.3% | -5.6% |
| 3m | -54.0% | -4.9% |
| 6m | -59.3% | -0.4% |
| 1y | — | +9.6% |
| ytd | — | +7.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AVEX Fundamental Analysis
Revenue is growing at an exceptional clip, with Q2 2026 revenue of $201.79 million representing 99.53% year-over-year growth versus Q2 2025's $101.13 million. The multi-quarter trajectory shows sequential acceleration in absolute dollars — $121.24 million in Q3 2025, $157.31 million in Q4 2025, $216.69 million in Q1 2026, and $201.79 million in Q2 2026 — with the Q1-to-Q2 dip likely reflecting timing rather than demand deterioration given the near-doubling YoY. Product revenue of $168.67 million dwarfs service revenue of $33.12 million, confirming this is a hardware-led defense platform where manufacturing scale and contract wins drive the top line; the growth trend supports a credible
Quarterly Revenue
$201791000.0B
2026-06
Revenue YoY Growth
+99.5%
YoY Comparison
Gross Margin
23.6%
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AVEX Overvalued?
Because trailing net income is effectively zero (EPS of -$0.00049 and a trailing PE of -97.5), the PE ratio is not a meaningful anchor; the appropriate primary metric is the price-to-sales ratio of 3.99x, supplemented by EV/EBITDA of 54.09x. The forward PE is listed as 0 and the PEG ratio as 0, meaning no forward earnings multiple is available in the dataset, but consensus estimated EPS of $1.335 against a $10.20 price implies a forward multiple of roughly 7.6x — a dramatic gap versus the trailing figures that signals the market is either deeply skeptical of that estimate or pricing in substantial execution risk.\n\nOn a peer basis, a 3.99x PS ratio and 54.09x EV/EBITDA sit at a premium to typical Aerospace & Defense multiples (large-cap primes generally trade in the 1.5x-2.5x sales and 12x-16x EBITDA range), though the dataset does not provide an explicit industry average for direct comparison. The premium is defensible only if the ~100% revenue growth is durable; against a 21.78% gross margin and a 1.00% operating margin, the company earns far less per dollar of revenue than legacy defense contractors, which typically post mid-teens operating margins. The 7.01x price-to-book ratio further reflects a market valuation built on growth expectations rather than current returns, given ROE of -0.34%.\n\nHistorical context is limited because AVEX listed in April 2026, but the available ratio history is instructive: PS compressed from 5.85x at Q2 2026 to 3.99x now, and PE moved from 126.76x to a negative trailing figure as earnings normalized toward breakeven. The stock is therefore near the low end of its own short valuation band, which could represent a value opportunity if growth holds — or reflect fundamental deterioration if the October collapse was catalyst-driven. With a dividend yield of just 0.29% and a negative payout ratio of -5.90, there is no income support to cushion the valuation.
PE
-97.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
39.4x
Industry PE ~39.4x*
EV/EBITDA
54.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a valuation that requires continued hyper-growth to justify itself. Revenue grew 99.53% year-over-year to $201.79 million in Q2 2026, but gross margin of 21.78% and operating margin of 1.00% leave almost no buffer, and Q2 net income of just $2.33 million on $201.79 million of revenue shows how thin the profit layer is. The Q1-to-Q2 sequential revenue decline from $216.69 million to $201.79 million, combined with a revenue estimate band of $1.19 billion to $1.42 billion, quantifies contract-timing risk: a slip of a few programs could push growth well below the ~100% run-rate and compress margins as fixed costs absorb slower volume. Interest expense of $3.98 million in Q2 and $6.54 million in Q1, against debt-to-equity of 0.43, is manageable but consumes a meaningful share of operating income of $15.37 million.
Market and competitive risks are dominated by valuation compression and post-IPO share overhang. At 3.99x sales and 54.09x EV/EBITDA versus typical Aerospace & Defense multiples of 1.5x-2.5x sales and 12x-16x EBITDA, AVEX carries a premium that can compress sharply if growth normalizes; PS has already fallen from 5.85x at Q2 2026 to 3.99x now, and the trailing PE moved from 126.76x to -97.5x as earnings normalized toward breakeven. The October 21 gap from $14.34 to $9.68 — roughly 32% in one session — is consistent with a lockup expiry or large-block sale, and the stock has underperformed SPY by 49.08 points over three months and 58.77 points over six months. Beta is not provided, but realized volatility (multiple 20%+ single-day moves and a 77.12% peak-to-trough drawdown) implies far higher market correlation and drawdown risk than a typical Industrials holding, and competition from better-capitalized primes and other defense-tech entrants could pressure both pricing and contract awards.
The worst-case scenario is a negative Q3 print that confirms deceleration, combined with continued post-lockup insider supply, which would break the $9.26 November 5 low and open a vacuum with no historical support beneath it. From the current $10.20, a move to the $9.26 recent low is roughly -9%, but a capitulation scenario toward the $7-$8 area — implied by applying a 2.5x-3.0x sales multiple to the low end of the $1.19 billion revenue estimate — would represent a decline of roughly -22% to -31%. The realistic downside range is therefore -9% to -31% from current levels, and the historical max drawdown of -77.12% from the $40.48 peak demonstrates how severe the tail can be when a high-multiple IPO name loses its growth narrative.
FAQ
Ranked by severity: first, growth-deceleration risk — revenue estimates span $1.19 billion to $1.42 billion, and a print near the low end would leave a 21.78% gross margin and 1.00% operating margin unable to support even the current 3.99x sales multiple. Second, post-lockup supply risk — the October 21 gap from $14.34 to $9.68 (roughly 32% in one session) is consistent with a block sale or lockup expiry, and a second tranche could break the $9.26 November 5 low into a vacuum with no historical support. Third, profitability and cash risk — Q2 net income was just $2.33 million on $201.79 million of revenue, trailing EPS is -$0.00049, and price-to-cash-flow is -17.68, so there is no earnings or cash cushion. Fourth, valuation and momentum risk — at 54.09x EV/EBITDA with a -77.12% max drawdown and -49.08 points of three-month relative underperformance versus SPY, further multiple compression is a live threat independent of operating results.
The scenario framework assigns 50% to a base case of $12-$15, 25% to a bull case of $18-$22, and 25% to a bear case of $7-$9.26. The base case assumes Q3 revenue annualizes near the $1.35 billion consensus, gross margin holds in the 22-24% range, and the stock chops between the $9.26 low and the $14.34 pre-gap level without a re-rating catalyst. The bull case requires revenue near the $1.42 billion high estimate plus a large uncrewed-systems or ISR award and the first published sell-side targets, driving a re-rate toward the June 30 rebound high of $20.89. The bear case assumes a deceleration print plus renewed insider supply, breaking $9.26 and applying a 2.5x-3.0x sales multiple to the low-end revenue estimate. The base case is most likely, and its key assumption is that the ~100% growth rate moderates rather than collapses.
The answer depends on which metric you anchor to, and the gap between them is unusually wide. Trailing PE is -97.5 on EPS of -$0.00049, so earnings multiples are meaningless; the operative trailing metrics are 3.99x PS, 54.09x EV/EBITDA, and 7.01x price-to-book, all premium to the 1.5x-2.5x sales and 12x-16x EBITDA typical of large-cap Aerospace & Defense primes. Against that, consensus EPS of $1.335 implies a forward multiple near 7.6x, which would be deeply undervalued if achieved. Within its own short history, PS has compressed from 5.85x at Q2 2026 to 3.99x now, placing the stock near the low end of its valuation band. The market is therefore pricing skepticism about the durability of ~100% growth and the thin 21.78% gross margin — the discount is only real if the growth rate holds.
The risk/reward is unresolved rather than clearly favorable. On the positive side, revenue grew 99.53% YoY to $201.79 million in Q2 2026, gross margin expanded from 14.09% to 23.61%, and consensus EPS of $1.335 against a $10.20 price implies roughly 7.6x forward earnings — cheap if that estimate is real. On the negative side, the stock is down 74.8% from its $40.48 peak with a -77.12% max drawdown, -28.32% in one month, and a fresh low of $9.26 on November 5, and the dataset contains no published analyst price targets to verify any upside. The biggest downside risk is a capitulation toward $7-$8 if growth decelerates to the $1.19 billion low revenue estimate. It is a reasonable speculative buy only for investors who can tolerate a 25-30% further drawdown and who wait for confirmation — a Q3 print near the $1.35 billion consensus plus a reclaim of $14.34 — rather than catching the falling knife at $10.20.
AVEX is structurally a long-term holding candidate but currently behaves like a trading vehicle. The company listed only in April 2026, so it has roughly seven months of public trading history, no published analyst price targets, and earnings visibility limited to a tight EPS band ($1.1337-$1.43149) against a wide revenue band ($1.19-$1.42 billion) — all markers of an early-stage, low-visibility name. Volatility is extreme: a -77.12% max drawdown, multiple 20%+ single-day moves, and -53.99% over three months make short-term trading a momentum bet with poor odds given the broken trend. The 0.29% dividend yield and negative payout ratio of -5.90 mean there is no income reason to hold. A minimum holding period of 12-18 months is appropriate, sized as a small speculative allocation, with the position re-evaluated after at least two clean quarterly prints confirm whether the growth rate is durable.